ORIC PHARMACEUTICALS INC. - COMMON STOCK

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

27 Aug 2025 13:05:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

18 Aug 2025 13:05:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

12 Aug 2025 13:05:01 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Aug 2025 13:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Jul 2025 13:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 Jun 2025 13:30:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

28 May 2025 13:05:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

28 May 2025 13:05:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

27 May 2025 13:30:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

27 May 2025 05:00:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

05 May 2025 13:05:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 May 2025 13:30:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

28 Apr 2025 13:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2025 13:30:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

31 Mar 2025 13:30:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

25 Mar 2025 13:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 Mar 2025 13:30:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

25 Feb 2025 13:15:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

18 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 Feb 2025 13:30:00 By Nasdaq GlobeNewswire